Anti-LOXL1 Polyclonal Antibody for WB, IF-P, ELISA - Q08397

Core Product Specifications and Parameters

Biological Background: LOXL1 Function and Localization

• LOXL1 is a member of the lysyl oxidase gene family, encoding a secreted copper-dependent amine oxidase that initiates covalent cross-linking of collagen and elastin fibers.
• It catalyzes the oxidative deamination of peptidyl lysine and hydroxylysine residues, a critical step for the stabilization and maintenance of extracellular matrix integrity.
• Expressed in various tissues, with notable presence in ocular structures such as the iris, ciliary body, lens, and optic nerve; absent in retina.
• Subcellularly localizes to the extracellular space and associates with the extracellular matrix after secretion.
• Contains essential domains including a catalytic LTQ cofactor and copper-binding sites, characteristic of lysyl oxidases.
• Genetic variants in LOXL1 are strongly associated with exfoliation syndrome and glaucoma, highlighting its role in ocular matrix homeostasis.
• Undergoes proteolytic processing, with cleavage on pairs of basic residues, contributing to its activation.

Experimental Guidance and Technical Tips

• The immunogen targets amino acids 95-370 of human LOXL1, a central region; consider using peptide blocking or recombinant protein to confirm antibody specificity in your assay.
• For WB, the predicted molecular weight is ~63 kDa; however, post-translational modifications and processing may lead to multiple bands; optimize reducing conditions and sample preparation.
• This antibody shows cross-reactivity with mouse LOXL1; validate species-specific reactivity using appropriate controls and consider sequence homology alignment.
• For IF-P, permeabilization may be required to detect intracellular precursor forms; as LOXL1 is secreted, co-staining with ER/Golgi markers can help localize the protein.

CamelBio: Your One-Stop Sourcing Bridge

CamelBio is your one-stop sourcing partner for IVD raw materials, supporting every stage from concept to clinic. This anti-LOXL1 polyclonal antibody is part of our extensive portfolio targeting extracellular matrix remodeling and ocular disease research. Beyond antibodies, we offer validated antibody pairs, optimized monoclonal/polyclonal reagents, bulk ancillary materials, and rare-target raw-material sourcing to accelerate your diagnostic development.